Clinical trials in Bad Krozingen – page 30

689 clinical trials in Bad Krozingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Bad Krozingen at a glance

689

clinical trials

Research sites1

Quick filters

689 trials in Bad Krozingen

Open in trial search

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Surabgene lomparvovec
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Rheumatoid arthritis+1

Not yet recruiting

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

HIV infection

Not yet recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bictegravir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Norucholic Acid
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Glioma

Not yet recruiting

Study of L19TNF and Lomustine for Patients with Recurrent or Progressive Glioblastoma

Registered drugNo placebo

Study of L19TNF and Lomustine for Patients with Recurrent or Progressive Glioblastoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Philogen S.p.A.

Contact Research Centre

Pancreatic carcinoma metastatic

Not yet recruiting

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:University Of Cologne

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Carfilzomib
Sponsor:Intergroupe Francophone Du Myelome

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:BioNTech SE

Contact Research Centre

Acute graft versus host disease

Not yet recruiting

Study of RLS-0071 in Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

InvestigationalNo placebo

Study of RLS-0071 in Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Realta Life Sciences Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Bad Krozingen

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein management and preventive therapies for cardiovascular disease, exploring new treatments to reduce major cardiovascular events in high-risk patients.

Cardiovascular death prevention
Stroke prevention
Myocardial infarction management

Advanced studies evaluating novel therapeutic approaches for better cardiovascular outcomes.

02 Thrombosis and Embolism

Clinical investigations into deep vein thrombosis treatments and prevention of systemic embolism, particularly in patients with atrial fibrillation.

Clot lysis therapy
Pulmonary embolism treatment
Anticoagulation strategies

Comprehensive research on blood clot prevention and treatment methodologies.

03 Cardiac Conditions

Studies addressing hypertension management and innovative treatments for acute coronary syndromes, including specialized interventions for heart attack prevention.

Blood pressure control
Acute myocardial infarction
Coronary interventions

Evaluating cutting-edge therapies for various cardiac conditions.

04 Vascular Health

Research focusing on peripheral arterial disease and advanced vascular interventions, including novel contrast medium strategies for better patient outcomes.

Peripheral vascular interventions
Kidney protection strategies
Vascular disease management

Developing safer and more effective vascular treatment approaches.

Back to Germany All countries